Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameYzybio-B
Stock Code02496
Company Full NameTo be extracted
Industry醫療保健
Principal Activities公司是一家致力于開發用于治療癌癥相關并發癥、癌癥及老年性眼科疾病的BsAb療法的生物技術公司。
Listing Date2023-09-25
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國湖北省武漢市東湖新技術開發區高新大道666號
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehttps://www.yzybio.com/
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo data

Offering Information

Offering Mechanism To be extracted
Offer PriceHK$ 16.00 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer PeriodTo be extracted
Global Offering SharesTo be extracted
HK Public Offer Shares (Initial)To be extracted
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)To be extracted
Offer RatioTo be extracted
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)To be confirmed
Stabilizing Manager (Greenshoe)—
Cornerstone Share59.2%
Clawback TiersTo be extracted
Reallocation OptionTo be confirmed
Total Global Offering SizeHK$ 17,603,200

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 200 HK$ 3,200
2 lots 400 HK$ 6,400
3 lots 600 HK$ 9,600
4 lots 800 HK$ 12,800
5 lots 1,000 HK$ 16,000
6 lots 1,200 HK$ 19,200
7 lots 1,400 HK$ 22,400
8 lots 1,600 HK$ 25,600
9 lots 1,800 HK$ 28,800
10 lots 2,000 HK$ 32,000
15 lots 3,000 HK$ 48,000
20 lots 4,000 HK$ 64,000
25 lots 5,000 HK$ 80,000
30 lots 6,000 HK$ 96,000
35 lots 7,000 HK$ 112,000
40 lots 8,000 HK$ 128,000
45 lots 9,000 HK$ 144,000
50 lots 10,000 HK$ 160,000
75 lots 15,000 HK$ 240,000
100 lots 20,000 HK$ 320,000
125 lots 25,000 HK$ 400,000
150 lots 30,000 HK$ 480,000
175 lots 35,000 HK$ 560,000
200 lots 40,000 HK$ 640,000
250 lots 50,000 HK$ 800,000
300 lots 60,000 HK$ 960,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway None
Avg Daily HK Mkt Cap ---
Est. Threshold ---
Analysis Result 无法确定入通路径

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted
First Day CloseHK$ 16.0
First Day OpenHK$ 16.4
First Day Change-67.75%
First Day Volume1519600.0
First Day Turnover24912300.0
Use of Proceeds
1、約80%或約97.1百萬港元將用作核心產品M701計劃進行的臨床試驗、擬備注冊備案文件及商業化推出計劃; 2、約12%或14.6百萬港元將用作Y101D計劃進行的臨床試驗; 3、約8%或9.7百萬港元將用作營運資金和一般公司用途。

Underwriting Syndicate

Sole Sponsor (1)
中信建投(国际)融资有限公司 CE BAU112
Overall Coordinators (3)
中信建投(国际)融资有限公司 CE BAU112 国泰君安证券(香港)有限公司 CE ABY236 建银国际金融有限公司 CE AJO225
Joint Bookrunners (6)
中信建投(国际)融资有限公司 CE BAU112 国泰君安证券(香港)有限公司 CE ABY236 建银国际金融有限公司 CE AJO225 BOCI ASIA LIMITED CE AET863 TFI Securities and Futures Limited CE BAV573 中国银河国际证券(香港)有限公司 CE AXM459
Joint Lead Managers (8)
中信建投(国际)融资有限公司 CE BAU112 国泰君安证券(香港)有限公司 CE ABY236 建银国际金融有限公司 CE AJO225 BOCI ASIA LIMITED CE AET863 TFI Securities and Futures Limited CE BAV573 中国银河国际证券(香港)有限公司 CE AXM459 Livermore Holdings Limited CE BJN764 富途证券国际(香港)有限公司 CE AZT137

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 成都朴华凯智生物科技有限公司 21,481,600 HKD — 12.20% — 6 months 2024-03-25
2 武汉光谷健康产业投资有限公司 42,976,000 HKD — 24.42% — 6 months 2024-03-25
3 武汉市楚兴友瑞大健康产业投资基金合伙企业(有限合伙) 39,763,200 HKD — 22.59% — 6 months 2024-03-25

Directors & Management

PositionChinese nameEnglish Name
ChairmanZhou Pengfei—
Company Secretary鄭建華;賴天恩—
No director data available.

Major Shareholders

Major Shareholders & Holdings袁謙(10.57%);武漢才智投資管理合伙企業(有限合伙)(8.70%);周宏峰(5.28%)
About this page

This page shows Yzybio-B (02496) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect